Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Surgery
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an unblinded, parallel group randomized controlled trial to evaluate bright green light as an adjunct therapy after surgery at UPMC Shadyside. The primary outcome measure will be pain intensity with secondary outcome measures including opioid requirements, sleep quality, mood, and overall post-operative recovery. Specific aims/hypotheses for this study are as follows: Aim 1: To assess bright green light therapy's potential as a complementary post-operative analgesic strategy in patients recovering from surgery Hypothesis 1: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved postoperative pain scores and lower opioid use. Aim 2: To examine the impact of bright green light therapy on patient-centered measures of post-operative recovery that may be related to improved circadian function. Hypothesis 2: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved quality of post-operative recovery, enhanced sleep, and reduced anxiety and depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Bright Green Light Therapy — Day Light Classic Plus light therapy lamp with filter to yield bright green light.
  • Device: Dim White Light Therapy — Day Light Classic Plus light therapy lamp with filter to yield dim white light.

Primary Outcomes

  • Incisional Pain Intensity with Movement (Post-Operative Day 2)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-14
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rebecca E Kotcher, MD
Principal Investigators:
  • Rebecca Kotcher, MD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh, UPMC
Contact Information
Study Contact:
Amy Monroe, MPH, MBA
412-623-6382
monroeal@upmc.edu
Dayana Alsamsam, BSPS, MSc
alsamsamd@upmc.edu
Amy Monroe, MPH, MBA
412-623-6382
monroeal@upmc.edu
UPMC Shadyside Hospital
Interventions
  • Device: Bright Green Light Therapy — Day Light Classic Plus light therapy lamp with filter to yield bright green light.
  • Device: Dim White Light Therapy — Day Light Classic Plus light therapy lamp with filter to yield dim white light.
Study Locations (1 sites)
UPMC Shadyside Hospital, Pittsburgh, Pennsylvania 15232 United States
Eligibility Criteria
Inclusion Criteria: * Age \>/= 18 years * Planned to undergo laparoscopic or robotic surgery at UPMC Shadyside Hospital * Anticipated post-operative length of stay \>/= 48 hours * Able to speak and read English fluently, with the capacity to provide informed consent and complete the associated surveys independently Exclusion Criteria: * Pregnancy * History of significant ocular issues/dysfunction (†‡ ) (e.g., glaucoma, ocular trauma, macular degeneration, cataracts) that would interfere with the ocular mechanism of action * History of significant neurological disease (‡) (e.g., traumatic brain injury, stroke, neurodegenerative disease) that would compromise the reliability of pain screening and/or interfere with the central mechanism of action * History of bipolar disorder or schizophrenia, which could increase the risk of an adverse reaction to light exposure (i.e., acute mania) * History of splenectomy, which would interfere with the mechanism of action * Ocular issues corrected with contact lenses or spectacle corrective eyeglasses will NOT be considered a criterion for exclusion ‡Unclear cases will be at the discretion of the PI
Conditions Asthma Control, Pulmonary Function, Qual...
Phase NA
Enrollment 80
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary goal of this study is to investigate the comparative long-term (i.e., 1-year) effectiveness of energy recovery ventilators (ERVs) and portable air cleaners (PACs) in reducing indoor air pollutants and mold levels and improving asthma-related health outcomes in inner-city children and adults with asthma in low-income households in the Dallas-Fort Worth (DFW) metropolitan area, TX. Secondary goals include: (1) examining associations among asthma outcomes, exposure to indoor air pollutants and mold, and housing-related factors, (2) conducting a cost-benefit analysis of ERV and PAC interventions for improving IAQ, mold control, and health outcomes, and (3) evaluating the utility of cost-effective methods and protocols for measuring IAQ and mold for indoor air pollution epidemiology studies and for providing practical information to patients and their physicians. Using a double-blind, placebo-controlled randomized controlled trial, 80 households will be assigned to receive active or placebo versions of ERVs or PACs. Environmental exposures and housing conditions will be monitored alongside comprehensive health assessments, including lung function tests and validated surveys on asthma control, quality of life, stress, and sleep quality.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Energy Recovery Ventilator — A mechanical ventilation system that exchanges stale indoor air with fresh outdoor air while transferring heat and moisture between the incoming and outgoing air streams
  • Device: Portable Air Cleaner — A standalone home device that filters indoor air to remove particulate matter, allergens, and other pollutants
  • Device: Energy Recovery Ventilator (Sham) — A home-installed ERV unit that operates in recirculation mode only, providing no fresh air exchange or heat/moisture transfer, serving as a placebo for study purposes.
  • Device: Portable Air Cleaner (Sham) — A portable air cleaner that appears to operate like an active unit but does not contain a HEPA filter and does not clean the air, serving as a placebo for study purposes

Primary Outcomes

  • Pulmonary Function (Spirometry) (Baseline; 6 months; 18 months; 24 months)
  • Asthma Control Test Score (From enrollment to the end of intervention at 1 month (24 months in total))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-10
Completion: 2028-02-28
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas at Arlington
Collaborators: Rebuilding Together North Texas
Principal Investigators:
  • Insung Kang, Ph.D. (PRINCIPAL_INVESTIGATOR) - The University of Texas at Arlington
Contact Information
Study Contact:
Insung Kang, Ph.D.
817-272-2167
insung.kang@uta.edu
Insung Kang, Ph.D.
312-342-5733
insung.kang@uta.edu
University of Texas at Arlington
June Young Park, Ph.D.
University of Texas at Arlington
Interventions
  • Device: Energy Recovery Ventilator — A mechanical ventilation system that exchanges stale indoor air with fresh outdoor air while transferring heat and moisture between the incoming and outgoing air streams
  • Device: Portable Air Cleaner — A standalone home device that filters indoor air to remove particulate matter, allergens, and other pollutants
  • Device: Energy Recovery Ventilator (Sham) — A home-installed ERV unit that operates in recirculation mode only, providing no fresh air exchange or heat/moisture transfer, serving as a placebo for study purposes.
  • Device: Portable Air Cleaner (Sham) — A portable air cleaner that appears to operate like an active unit but does not contain a HEPA filter and does not clean the air, serving as a placebo for study purposes
Study Locations (2 sites)
University of Texas at Arlington, Arlington, Texas 76010 United States
Rebuilding Together North Texas, Plano, Texas 75025 United States
Eligibility Criteria
Inclusion Criteria: * Individuals with physician-diagnosed asthma, including both adults and children aged 5-17 * Homeowners living in the DFW metropolitan area, TX Exclusion Criteria: * Participants living in homes with any smokers
Conditions Breast Cancer, Breast-conserving Surgery...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes deliberate controlled damage to the tissue surrounding where the tumor was located. You may hear your doctor refer to this as the 'margins'. Your doctor is using this treatment to help destroy remaining cancer cells in the margins around the site of the lump.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Radiofrequency ablation alone — Demonstrate the accuracy of the device to produce approximately 1 cm depth of ablation around the tumor bed, as evaluated by post-ablation tissue samples at least 1cm deep.
  • Device: Radiofrequency ablation Electrosurgical Device — SIRA-1000 an radiofrequency ablation device, is designed to fit the post-lumpectomy cavity to provide uniform ablation.

Primary Outcomes

  • To assess the safety of SIRA-1000 by summarizing the occurrence of Adverse Events. (The study will span a total of approximately 12 months with a follow-up for 5 years.)
  • Healing Process assessed by BREAST-Q Questionnaire (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-10
Completion: 2032-02-06
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Innoblative Designs, Inc.
Principal Investigators:
  • V. Suzanne Klimberg, MD, PhD, MSCHT, MAMSE, FACS (STUDY_CHAIR) -
Contact Information
Study Contact:
Clinical Trials Manager
833-920-4660
kathy@innoblative.com
VP Quality Assurance & Regulatory Affairs
833-920-4660
kcrowley@innoblative.com
Sr. Clinical Research Coordinator
409-772-1983
jearober@utmb.edu
University of Texas Medical Branch at Galveston, TX
Interventions
  • Device: Radiofrequency ablation alone — Demonstrate the accuracy of the device to produce approximately 1 cm depth of ablation around the tumor bed, as evaluated by post-ablation tissue samples at least 1cm deep.
  • Device: Radiofrequency ablation Electrosurgical Device — SIRA-1000 an radiofrequency ablation device, is designed to fit the post-lumpectomy cavity to provide uniform ablation.
Study Locations (1 sites)
University of Texas Medical Branch at Galveston, TX, Galveston, Texas 60612 United States
Eligibility Criteria
Inclusion Criteria: 1. Biologic female 2. 50 years of age and older 3. Confirmed diagnosis of breast cancer: 1. Infiltrating ductal carcinoma 2. ER/PR+Her2neu- 3. Grade I, II, or III 4. Unicentric, unilateral tumor size ≤ 3cm 5. Tumor location ≥ 2 cm from skin and other structures 6. Zubrod Performance Status of 0, 1, or 2 7. No palpable lymphadenopathy 8. Able and willing to provide written informed consent Exclusion Criteria: 1. Pregnant or breastfeeding 2. Neoadjuvant chemotherapy 3. Cardiac arrhythmia 4. Patients with active implantable medical devices, such as implanted cardiac pacemakers or defibrillators, or any other electronic device 5. Current or history of breast implants 6. Multi-centric or bilateral breast cancer 7. Diffuse microcalcifications 8. Participating in another ongoing clinical study in which concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter the outcomes under study 9. Has a condition or is in a situation which in the Investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
Conditions Kidney Diseases, Food/Nutrition Insecuri...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pilot clinical trial is primarily learn if produce boxes improve clinical outcomes among Veterans with kidney disease and food or nutrition insecurity. Secondly, the study will capture Veterans qualitative perspectives, experience, and engagement through semi-structured interviews.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: VET FAM Product Box and Nutrition Education — Food boxes and nutrition education

Primary Outcomes

  • Systolic Blood Pressure (Baseline (0-months), 3-months, and 6-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Eastern Colorado Health Care System
Collaborators: Food Bank of the Rockies, National Kidney Foundation, United States
Principal Investigators:
  • Luis M Perez, PhD, RD (PRINCIPAL_INVESTIGATOR) - US Department of Veterans Affairs
Contact Information
Study Contact:
Luis M Perez, PhD, RD
720-467-0757
luis.perez2@va.gov
Luis M Perez, PhD, RD
Rocky Mountain Regional VA Medical Center
Luis M Perez, PhD, RD
Rocky Mountain Regional VA Medical Center
Interventions
  • Other: VET FAM Product Box and Nutrition Education — Food boxes and nutrition education
Study Locations (1 sites)
Rocky Mountain Regional VA Medical Center, Aurora, Colorado 80045 United States
Eligibility Criteria
Inclusion Criteria: * Age 18+ * CKD stage 3b or 4 * Positive screen for nutrition insecurity (e.g., Tufts screener) * Receiving care at the VA and residing in Food Bank of the Rockies service area * Ability to provide informed consent, English Exclusion Criteria: * Stage 1-3a CKD and stage 5 CKD/ESRD (dialysis or transplant) * Currently enrolled in a conflicting dietary trial * Unwilling or unable to provide informed consent
Conditions ALND, Sentinel Lymph Node Biopsy (SLNB),...
Phase Not Applicable
Enrollment 150
Locations 14 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The present study aims to avoid axillary lymph node dissection (ALND) in patients with an Ultrasound (US) detected positive preoperative lymph node involvement (1 or 2 suspicious lymph-nodes) and a needle histology/cytology placing a marker in the most suspicious node undergoing upfront surgery if neoadjuvant treatment is not indicated. The marked lymph node will be retrieved along with sentinel lymphnode(SLN)(s) to minimize the false-negative rate and only in case of ≥3 positive SLNs ALND will be performed, in order to minimize surgical overtreatment among women with preoperatively confirmed axillary nodal metastasis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Upfront Targeted Axillary Dissection (UTAD) — During the surgical intervention lymphnodes excised both with reflector localization and Gamma probe will be sent for pathological examination and only in case of more than 2 metastatic lymph nodes (and at least one of them with macrometastasis) axillary dissection will be performed.

Primary Outcomes

  • Successful rate of the retrieval of the deflector. (Perioperative/Periprocedural)
  • Prevention of Axillary Lymph Node Dissection (Perioperative/Periprocedural)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-28
Completion: 2033-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Contact Information
Study Contact:
Viviana Galimberti, MD
+39 0257489717
viviana.galimberti@ieo.it
Marco Bernini, MD
+39 051 2143344
marco.bernini@aosp.bo.it
IRCCS AOU di Bologna - Policlinico di Sant'Orsola
Marco Bernini, MD
IRCCS AOU di Bologna - Policlinico di Sant'Orsola
Interventions
  • Procedure: Upfront Targeted Axillary Dissection (UTAD) — During the surgical intervention lymphnodes excised both with reflector localization and Gamma probe will be sent for pathological examination and only in case of more than 2 metastatic lymph nodes (and at least one of them with macrometastasis) axillary dissection will be performed.
Study Locations (14 sites)
IRCCS AOU di Bologna - Policlinico di Sant'Orsola, Bologna, Italy 40138 Italy
AUSL Romagna - Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy 47121 Italy
European Institute of Oncology, Milan, Italy 20141 Italy
Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy 20133 Italy
Azienda Ospedaliera Universitaria Federico II, Naples, Italy 80131 Italy
Presidio Ospedaliero "G. Bernabeo", Ortona, Italy 66026 Italy
Policlinico San Matteo, Pavia, Italy 27100 Italy
Azienda Ospedaliera Universitaria Pisana, Pisa, Italy 56100 Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy 00136 Italy
AO San Giovanni Addolorata, Roma, Italy 00184 Italy
Eligibility Criteria
Inclusion Criteria: * Diagnosis of T0-T1-T2 ER+/PR+ HER2- breast cancer with limited nodal involvement (1 or 2 suspicious lymph node on US, with at least 1 nodal positive cytology/histology) * M0 * Conservative surgery or mastectomy * Neoadjuvant treatment not recommended after a multidisciplinary discussion * Patients between 18 and 90 years old * Patients willing and able to follow the study procedures and available for follow-up over the entire duration of the study Exclusion Criteria: * Psychiatric, addictive or any disorder, which compromises ability to give informed consent for participation in the study * Personal history of invasive breast cancer * Other invasive malignancies diagnosed in the last five years * Any condition that may expose the individual to a higher risk or preclude the study from achieving full compliance or completion * Contraindications to radiation therapy
Conditions Sleep Disorder (Disorder), Anxiety Depre...
Phase NA
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to examine the effectiveness of Avance eZZe drink with liposomal technology in improving sleep quality. Participants will be randomly assigned to either the placebo group, Avance eZZe drink group, and Avance eZZe drink without liposomal group, with 25 participants in each group. On the day of the experiment (day 0), participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. Subsequently, participants will be given the experimental samples and instructed to consume them 1 hour before sleep daily for 28 days. Follow-up assessments will be conducted in the day-1, day-14 and day-28, participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Avance eZZe drink — 25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
  • Dietary Supplement: Avance eZZe drink (without liposomal) — 25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
  • Dietary Supplement: Placebo drink — 25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily

Primary Outcomes

  • Sleep monitoring (Day-0 (baseline), Day-1, Day-14, Day-28)
  • Sleeping quality (Day-0 (baseline), Day-14, Day-28)
  • Insomnia Severity (Day-0 (baseline), Day-14, Day-28)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-09
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: TCI Co., Ltd.
Principal Investigators:
  • Hsin-Chien Lee, Doctor (PRINCIPAL_INVESTIGATOR) - Taipei Medical University
Contact Information
Study Contact:
Hsin-Chien Lee, Doctor
+886-02-22490088
ellalee@tmu.edu.tw
Ping Lin
+886-02-87977811
candice.lin@tci-bio.com
Hsin-Chien Lee, Doctor
+886-02-22490088
ellalee@tmu.edu.tw
Taipei Medical University
Interventions
  • Dietary Supplement: Avance eZZe drink — 25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
  • Dietary Supplement: Avance eZZe drink (without liposomal) — 25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
  • Dietary Supplement: Placebo drink — 25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
Study Locations (1 sites)
Taipei Medical University, Taipei, 110 Taiwan
Eligibility Criteria
Inclusion Criteria: * Male or female age 18 years or older; * Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) criteria for Insomnia Disorder; * Regular bedtime, between 21:00 and 01:00 and regular wake time; * Insomnia Severity Index (ISI) score ≥15; * All medications or interventions for insomnia, mental or physical disorders must have been stable for at least four weeks prior to screening, and participants had to be willing to maintain a stable regimen throughout the study; * No consumption of sleep or stress-related supplements for at least four weeks prior to screening; * Willing and able to comply with all aspects of the protocol. Exclusion Criteria: * A current diagnosis of sleep-related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder; * Depressive symptoms at screening were considered significantly severe with a PHQ-9 score \> 14 * Anxiety symptoms at screening were considered significantly severe with a GAD-7 score \> 15; * Females who are breastfeeding or pregnant; * Females of childbearing potential who are not practicing acceptable pregnancy prevention methods (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically.); * Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia, or habitually consumes caffeine-containing beverages after 18:00 and is unwilling to forego caffeine after 18:00 for the duration of his/her participation in the study; * History of drug or alcohol dependency or abuse within approximately the previous 2 years; * Current evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal, neurological, or psychiatric disease or malignancy or chronic pain that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments; * Scheduled for major surgery during the study; * Participants known to be allergic to any components of the product.
Conditions Pulmonary Hypertension, Interstitial Lun...
Phase PHASE3
Enrollment 344
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Treprostinil Palmitil Inhalation Powder — Oral inhalation using a capsule-based dry powder.
  • Drug: Placebo — Oral inhalation in initial double-dummy titration period.

Primary Outcomes

  • Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs) (Up to 108 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-20
Completion: 2031-01-22
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 344 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insmed Incorporated
Principal Investigators:
  • Study Director (STUDY_DIRECTOR) - Insmed Incorporated
Contact Information
Study Contact:
Insmed Incorporated
18444467633
medicalinformation@insmed.com
Interventions
  • Drug: Treprostinil Palmitil Inhalation Powder — Oral inhalation using a capsule-based dry powder.
  • Drug: Placebo — Oral inhalation in initial double-dummy titration period.
Study Locations (9 sites)
USA006, Naples, Florida 34102 United States
USA003, Bend, Oregon 97701 United States
JPN004, Narita, Chiba 286-8520 Japan
KOR001, Seoul, 3080 South Korea
KOR006, Seoul, 6351 South Korea
ESP006, Madrid, 28041 Spain
ESP003, Madrid, 28046 Spain
ESP001, Seville, 41009 Spain
TWN003, Hsinchu, 30059 Taiwan
Eligibility Criteria
Inclusion Criteria * Participants who have completed the lead-in PH-ILD TPIP Study INS1009-311 (NCT07179380). * Capable of giving signed informed consent that includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Agree not to participate in any other interventional trials or use investigational drugs or devices while participating in the INS1009-312 study. Exclusion Criteria * Participants who experienced any adverse events (AEs) evaluated as causally related to TPIP by the Investigator in a lead-in study, which in the opinion of the Investigator, could pose an unreasonable risk of continued treatments for the participant. * Current use or expected need for pulmonary arterial hypertension (PAH)-approved therapy, including prostacyclin, prostacyclin analogues or other prostacyclin receptor agonists, endothelin receptor antagonists, and/or soluble guanylate cyclase stimulator, or any PH-ILD approved treprostinil therapy. Use of phosphodiesterase 5 inhibitors in line with applicable guidelines is allowed. * Diagnosis of Pulmonary Hypertension World Health Organisation (WHO) Groups 1, 2, 4, or 5, or subtypes of PH WHO Group 3 other than interstitial lung disease (including combined pulmonary fibrosis and emphysema). * Evidence of left ventricular failure, heart failure with preserved ejection fraction (HFpEF) or postcapillary PH. * Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (eg, mannitol, leucine). Note: Other protocol-defined inclusion/exclusion criteria may apply.
Conditions Diabetes
Phase PHASE3
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will be conducted to compare the efficacy, safety and patient-reported outcome of GZR4 and Insulin Icodec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: GZR4 — GZR4 s.c., once-weekly,treat-to-target dose
  • Drug: Insulin Icodec group — insulin Icodec s.c., once-weekly,treat-to-target dose

Primary Outcomes

  • Change in HbA1c (From baseline (week 0) to week 26)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-10-17
Completion: 2026-11-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gan & Lee Pharmaceuticals.
Contact Information
Study Contact:
juan wu
010-56456739
juan.wu@ganlee.com
juan wu
010-56456739
juan.wu@ganlee.com
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
Interventions
  • Drug: GZR4 — GZR4 s.c., once-weekly,treat-to-target dose
  • Drug: Insulin Icodec group — insulin Icodec s.c., once-weekly,treat-to-target dose
Study Locations (1 sites)
Gan & Lee Pharmaceuticals Shandong Co., Ltd., Linyi, Shandong 276000 China
Eligibility Criteria
Inclusion Criteria: * Sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and be able to follow the contraindications and restrictions specified in this protocol. * Males and females age ≥ 18 years at the time of informed consent. * The pregnancy test for β-human chorionic gonadotropin (hCG) must be negative for women of childbearing potential during the screening period and prior to randomization. * From signing the Informed Consent Form until 3 weeks after the end of treatment, female subjects of childbearing potential and male subjects and their partners must agree to use reliable contraceptive measures and not donate eggs (ova, oocytes) or sperm for assisted reproductive purposes. * According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with Hemoglobin A1c (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening. * Before screening, basal insulin was given once or twice a day. Or Insulin Icodec was given once-weeekly before screening. Exclusion Criteria: * A history of allergy to drugs with two or more mechanisms of action in the past, or known allergies, hypersensitivity, or intolerance to the investigational medicinal product or its excipients. * Subjects who are pregnant, lactating or planning to become pregnant during the study at screening. * Participated in any drug clinical study (received non-placebo medication during the study) within a recent period of time (90 days or 5 half-lives of the previous investigational medicinal product, whichever is longer), or plans to participate in another clinical study before completing all scheduled assessments in this clinical study. * Underwent invasive cardiovascular or cerebrovascular procedures within 180 days before screening; or experienced acute heart failure, myocardial infarction, stroke, or hospitalization due to angina unstable, transient ischaemic attack, or other acute cardiovascular events within 180 days before screening; or have a history of chronic cardiac failure classified as New York Heart Association Class III or IV at screening; or plan to undergo coronary, carotid, or peripheral arterial revascularisation procedures during the study; or have clinically significant abnormalities on the electrocardiogram (ECG) that the investigator considers inappropriate to participate in this study (such as second-degree type II or third-degree atrioventricular block, ventricular fibrillation, etc.). * History of malignant tumors within 5 years before screening (excluding adequately treated or resected non-metastatic basal or squamous cell skin cancer, cervical carcinoma in situ, or prostate cancer in situ) or the presence of underlying malignancy at screening. * The patient with SBP ≥ 160 mmHg or DBP ≥ 100 mmHg during screening. * Subjects who are unable to comply with the requirements of this protocol as judged by the investigator, or have any other conditions that the investigator considers inappropriate to participate in this study.
Conditions Cirrhosis, Microplastics, Portal Hyperte...
Phase Not Applicable
Enrollment 30
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cirrhosis and portal hypertension are associated with an hyperdynamic circulation and hepatic inflammation, leading to complications like ascites, variceal bleeding, acute kidney injury, and higher infection risk. Microplastics (MPs) are a global plastic pollution issue, and studies have found plastic MPs or nanoparticles (NPs) contaminating human, animal and environmental ecosystems.It has been noted that the accumulation of MPs increases with a reduction in size of the plastic particle. MPs are categorized into primary particles such as manufactured plastics including pellets and cosmetic microbeads and secondary particles which originate from mechanical and ultraviolet disruption of large plastic particles. MPs can be ingested via food or beverages, especially plastic packaged comestibles or inhaled as environmental pollutants. Contamination of medications such as antibiotics, intravenous fluids, albumin and medical devices is another source of exposure to microplastics in patients with chronic liver disease (CLD)In particular exposure to endoscopic interventions, liver biopsy, and invasive procedures such as paracentesis and interventional radiology procedures can lead to plastic exposure and deposition of MPs in the liver and other tissues in patients with cirrhosis. It may be hypothesized that these may contribute to hepatic inflammation and progression of cirrhosis and portal hypertension. Globally, there is new research on the influence of MPs on the environment, plant and animal ecosystems and human health. Polystyrene (PS) microspheres that concentrate in the liver, intestine and the kidneys of mammals disrupt lipid and energy metabolism, impair mucus secretion, and alter the microbiome. Therefore, studies are required to assess how and to what extent, MPs impact human health, and affect chronic diseases like cirrhosis and reduce longevity. The study investigators will assess the presence of MPs in the liver, kidneys and intestine of patients with liver cirrhosis and compare it with those without underlying liver disease and determine the impact on portal hypertension and fibrosis, and cardiovascular and metabolic function.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: Assessment of microplastics in tissue — After meeting inclusion and exclusion criteria, 30 patients with cirrhosis will be included in this study with written informed consent from patient (surgical cases) or scheduled liver biopsy. Diagnosis of chronic liver disease will be based on history, physical examination, laboratory investigations, upper gastrointestinal endoscopy as recorded in the patient file, imaging studies (ultrasonography and doppler of splenoportal venous axis). Underlying etiology of liver disease will be recorded. Complications of cirrhosis like hepatorenal syndrome (HRS), spontaneous bacterial peritonitis (SBP), upper gastrointestinal bleed, hepatic encephalopathy, acute kidney injury will be recorded from the patient's casefile. Tissue Sample Processing Standard laboratory solvents (i.e., acetonitrile, methanol, and water (LiChrosolv and SupraSolv grade) will be procured. The contact of laboratory surfaces and equipment will be minimized to reduce the risk of background contamination by plastics.

Primary Outcomes

  • The primary outcome is to assess MPs in human liver tissue, analysing their morphology, size, and composition (4-30 µm) in tissue samples from the liver inpatients with cirrhosis as compared with controls without cirrhosis (At time of enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-01
Completion: 2027-02-25
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Collaborators: Vellore Institute of Technology University
Principal Investigators:
  • Madhumita Premkumar (PRINCIPAL_INVESTIGATOR) - PGIMER Chandigarh
Contact Information
Study Contact:
Madhumita Premkumar, MD DM
01722754777
drmadhumitap@gmail.com
Dr. Madhumita Premkumar, MD
+919540951061
drmadhumitap@gmail.com
Dr. Madhumita Premkumar
Prerna Premkumar
01722754777
drmadhumitap@gmail.com
PGIMER Chandigarh
Interventions
  • Diagnostic Test: Assessment of microplastics in tissue — After meeting inclusion and exclusion criteria, 30 patients with cirrhosis will be included in this study with written informed consent from patient (surgical cases) or scheduled liver biopsy. Diagnosis of chronic liver disease will be based on history, physical examination, laboratory investigations, upper gastrointestinal endoscopy as recorded in the patient file, imaging studies (ultrasonography and doppler of splenoportal venous axis). Underlying etiology of liver disease will be recorded. Complications of cirrhosis like hepatorenal syndrome (HRS), spontaneous bacterial peritonitis (SBP), upper gastrointestinal bleed, hepatic encephalopathy, acute kidney injury will be recorded from the patient's casefile. Tissue Sample Processing Standard laboratory solvents (i.e., acetonitrile, methanol, and water (LiChrosolv and SupraSolv grade) will be procured. The contact of laboratory surfaces and equipment will be minimized to reduce the risk of background contamination by plastics.
Study Locations (2 sites)
Dr. Madhumita Premkumar, Chandigarh, Chandigarh 160012 India
PGIMER Chandigarh, Chandigarh, Chandigarh 160012 India
Eligibility Criteria
Inclusion Criteria: * Age range of 18-70 years * Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings. * Undergoing elective surgery or liver transplantation Exclusion Criteria: * • Hepatocellular carcinoma * Pregnancy or lactation * Patients with HIV or retroviral therapy * Prior liver interventions like locoregional therapy, presence of HCC, prior abdominal surgery
Conditions Resilience, Depressive Symptom, Anxiety
Phase NA
Enrollment 174
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-centre randomised controlled trial aims to examine the effects of a group-based gamified instrumental musical training in enhancing resilience (primary outcome), reducing psychological distress (depressive symptoms and anxiety), enhancing self-esteem, and improving HRQoL (secondary outcomes) among underprivileged school-aged children at risk of mental health problems (depression and anxiety) during a 12-month follow-up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Gamified music training — Instrumental musical training will progress from basic (playing simple notes) to advanced levels (playing an entire song). Key training elements will include fundamental music knowledge and skills, music improvisation, rhythm, and pitch identification exercises. In particular, the core concepts of resilience will be incorporated into the training process through various gamified music activities.
  • Behavioral: Active placebo intervention — Participants in the active placebo control group will participate in weekly 1-hour group-based indoor community leisure activities for 6 months. These activities will include (i) drawing, (ii) drama workshops, (iii) cartoon film screenings, (iv) handcraft workshops, (v) board games, and (vi) exercise classes. Each activity will span for four sessions, that is, totally 24 sessions and will be delivered by trained staff at the study centres of the collaborating non-governmental organisations.

Primary Outcomes

  • Resilience (Change from baseline to 12-month post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-08
Completion: 2027-09-30
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 174 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Contact Information
Study Contact:
Tan Cheung, PhD, MPhil
+85239430515
ankiecheung@cuhk.edu.hk
Assistant Professor, BN, MPhil, PhD
852 39430515
ankiecheung@cuhk.edu.hk
The Chinese University of Hong Kong
Interventions
  • Behavioral: Gamified music training — Instrumental musical training will progress from basic (playing simple notes) to advanced levels (playing an entire song). Key training elements will include fundamental music knowledge and skills, music improvisation, rhythm, and pitch identification exercises. In particular, the core concepts of resilience will be incorporated into the training process through various gamified music activities.
  • Behavioral: Active placebo intervention — Participants in the active placebo control group will participate in weekly 1-hour group-based indoor community leisure activities for 6 months. These activities will include (i) drawing, (ii) drama workshops, (iii) cartoon film screenings, (iv) handcraft workshops, (v) board games, and (vi) exercise classes. Each activity will span for four sessions, that is, totally 24 sessions and will be delivered by trained staff at the study centres of the collaborating non-governmental organisations.
Study Locations (1 sites)
The Chinese University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Hong Kong Chinese children aged 8-12 years. * Able to read Chinese and communicate in Cantonese/Mandarin. * From low-income families. * Have a risk of mental health problems, specifically depression and/or anxiety (determined through screening during the recruitment process using the Center for Epidemiological Studies Depression Scale for Children, with a cut-off score of ≥16 indicating a high risk of depression, and/or the State Anxiety Scale for Children, with scores between 36 and 60 indicating a significant level of anxiety) Exclusion Criteria: * Have chronic health conditions, cognitive and learning difficulties * if they or their siblings are currently receiving or have received any music-based interventions before the study.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This non-interventional study (NIS) aims to evaluate effectiveness, persistence, treatment patterns, adverse events (AEs), and patient-reported experience (including adherence, treatment satisfaction, health-related quality of life \[HRQoL\], work productivity, and etc.), among HR+/HER2- stage II and III eBC patients treated with ribociclib + ET, and to evaluate AEs and patients-reported experience among HR+/HER2- stage II and III eBC patients treated with abemaciclib + ET, as per local label.

Design

Study type: Observational Observational model: Other Time perspective: Other

Primary Outcomes

  • Invasive disease-free survival (iDFS) (36 months)
  • Distant disease-free survival (DDFS) (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-15
Completion: 2030-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Principal Investigators:
  • Novartis Pharmaceuticals (STUDY_DIRECTOR) - Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Novartis Pharmaceuticals
Interventions
N/A
Study Locations (1 sites)
Novartis Investigative Site, London, SW3 6JJ United Kingdom
Eligibility Criteria
Inclusion Criteria: * Males or females. * Diagnosed with breast cancer, as defined by the International Classification of Diseases (ICD), 9th or 10th Revision, Clinical Modification (ICD-9-CM 174.xx, 175.xx/ICD-10-CMC50.xx). * Aged ≥18 years (or local legal age of consent) at the date of initial breast cancer diagnosis. * Patients with anatomic staging II and III as determined using American Joint Committee on Cancer (AJCC) Criteria. * Have initiated adjuvant therapy with ribociclib or abemaciclib, per the approved local label, in combination with ET (within 14 days prior to enrollment). * Have HR+ status, as determined by the closest biomarker test on or before the adjuvant therapy initiation date: * Tested positive for estrogen receptor (ER+), or * Tested positive for progesterone receptor (PR+), or * Tested positive for both. * Tested negative for HER2 (HER2-) using the closest biomarker test on or before the adjuvant therapy initiation date. Exclusion Criteria: * Patients with local or distant breast cancer recurrence before the ribociclib/abemaciclib initiation date. * Patients enrolled in clinical trials (receiving treatment with clinical study drugs in any setting, i.e., neoadjuvant, adjuvant, local/regional, metastatic) during the 12-month baseline period. * Patients physically/mentally incapable of understanding the study requirements or fulfilling data collection instruments and require the support of a legally authorized representative.
Conditions Preeclampsia, Hypertensive Disorder of P...
Phase PHASE3
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to learn if postpartum women are willing to be randomized to different blood pressure medicines after delivery and how that affects blood pressure in women with hypertensive disorders of pregnancy.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Enalapril — First-line anti-hypertensive treatment with enalapril
  • Other: Standard treatment — First-line anti-hypertensive treatment per standard of care

Primary Outcomes

  • Feasibility of enrollment (4 months)
  • Feasibility of retention (4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-01-01
Completion: 2027-10-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Women and Infants Hospital of Rhode Island
Principal Investigators:
  • Alisse Hauspurg, MD (PRINCIPAL_INVESTIGATOR) - WOMEN AND INFANTS HOSPITAL-RHODE ISLAND
Contact Information
Study Contact:
Alisse Hauspurg, MD
401-274-1122
ahauspurg@carene.org
Crystal Ware, RN
cware@wihri.org
Alisse Hauspurg, MD, MS
401-274-1122
ahauspurg@carene.org
Women and Infants Hospital
Interventions
  • Drug: Enalapril — First-line anti-hypertensive treatment with enalapril
  • Other: Standard treatment — First-line anti-hypertensive treatment per standard of care
Study Locations (1 sites)
Women and Infants Hospital, Providence, Rhode Island 02906 United States
Eligibility Criteria
Inclusion Criteria: * Postpartum individuals * ≥18 years old * Hypertensive disorder of pregnancy * Enrolled in Women and Infants Hospital Hypertension Equity remote monitoring program. Exclusion Criteria: * Maternal cardiac disease * Individuals with pre-pregnancy hypertension or diabetes * Allergy or contraindication to enalapril